Business
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel
About this update from Renovorx, Inc.
[{"type":"text","content":" LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in Dana Point, CA.\n\n\nMr. Bagai will meet with investors and participate in a fireside chat hosted by Jonathan Aschoff, Senior Research Analyst at Roth MKM on Tuesday, March 19, 2024 at 10:00 am PT.\n\n\nMr. Bagai will discuss recent Company milestones, including an initial positive interim analysis on the Company’s pivotal Phase III TIGeR-PaC clinical trial. The study is evaluating the Company’s lead product candidate, RenovoGem™, and proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for the treatment of locally advanced pancreatic cancer.\n\n\nHe will also discuss other significant milestones achieved and the Company’s plans for 2024 and beyond, including recent completion of a $6.1 million private placement that has extended cash runway, allowing the Company to drive towards its key goal of a second interim analysis for TIGeR-PaC that will be triggered by the 52nd event (death), which is estimated to occur in late 2024.\n\n\nROTH MKM Healthcare Opportunities Conference\nDate: March 19, 2024\nTime: 10:00 AM PT\nSpeaker: Shaun Bagai, CEO\nLocation: The Ritz Carlton, Dana Point, CA\nWebcast: Registration Link\n\n\nTo schedule a one-on-one investor meeting with RenovoRx’s management team, please contact your ROTH MKM representative or KCSA Strategic Communications at [email protected].\n\n\nAbout RenovoRx, Inc.\n\n\nRenovoRx is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product ca...